A comprehensive clinical fmri software solution to enable mapping of critical functional networks and cerebrovascular reactivity in the brain
Active Project Grant Awarded Last action
- Award ID
- R01CA258788
- Recipient
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,914,389
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date 93% complete
- Place of performance
- Houston, TX 77030, USA
Award details come from USAspending.gov.
Description
- Abstract
- Functional localization of eloquent brain areas for patients undergoing surgery for brain tumors, epilepsy, or other neurological diseases is crucial to prevent post-surgical deficits and reduce morbidity. Task-based (TB) functional MRI (fmri), which detects blood oxygenation level-dependent (bold) signal changes while a patient performs task paradigms, is a standard-of-care clinical procedure for presurgical mapping of eloquent cortices. Two major limitations of clinical TB-fmri are a patient's inability to perform the task and lesion-induced impairment of neurovascular coupling (which drives the bold signal). Resting-state (RS) fmri, which measures synchronized bold signal oscillations during rest, can be used to map brain networks with minimal requirements for patient compliance and has been demonstrated to accurately localize motor and language areas for presurgical planning. Cerebrovascular reactivity (CVR) mapping, accessed by dynamic bold imaging during a hypercapnia task such as breath-holding, can be used to identify areas with potential false-negative fmri results due to neurovascular uncoupling (NVU) and has been suggested as an emerging standard to be used with clinical fmri. Currently, there are no commercially available FDA-cleared software tools for localizing the resting-state networks (rsns) or CVR. Clinical investigators have relied on research software packages that are either not clinically integrated or not yet optimized and validated in large patient populations. Thus, a vetted software solution is urgently needed to enable these state-of-the-art fmri methods to benefit patients beyond the limitations of TB-fmri. We hypothesize that enhancing, optimizing, and validating our preliminary software and integrating IT with an established commercial fmri platform will create robust solutions for clinical mapping of RSN and CVR. Through three specific aims, the software solutions will be optimized and tested with RS-fmri and CVR datasets from approximately 350 patients with brain tumors or epilepsy at three institutions. Aim 1 is to create the software for mapping rsns and determine optimized workflows for localizing eloquent areas including primary visual, motor (hands, tongue, and feet), and language (primary and secondary) areas. Both seed-based correlation and independent component analysis will be incorporated. Aim 2 is to create the software for mapping CVR and determine the optimized workflow for identifying and visualizing brain areas with potential false-negative fmri results. The software will include a multiple-latency general linear model and a unique graphical user interface to visualize the NVU. Aim 3 is to test and validate the software with presurgical fmri datasets. The results will be compared against those obtained from (1) processed using widely used research software packages, (2) TB- fmri, and (3) intraoperative direct cortical stimulation. This research is anticipated to create robust and clinically available software that will greatly increase the patient population who can benefit from presurgical fmri and will improve confidence in functional localization for surgical planning. This will directly benefit patients by preserving their post-surgical functions while allowing surgeons to safely maximize the resection of brain lesions.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $514,261 | |
| Amendment | $54,957 | |
| Amendment | $494,624 | |
| Amendment | $494,624 | |
| Amendment | $19,066 | |
| Amendment | $19,066 | |
| Amendment | $19,066 | |
| Amendment | $343,195 | |
| Amendment | $343,195 | |
| Amendment | $343,195 | |
| Amendment | $343,195 | |
| Amendment | $373,701 | |
| Amendment | $373,701 | |
| Amendment | $373,701 | |
| Amendment | $402,421 | |
| Original award | $402,421 |
Show all 16
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Childrens Mercy Hospital | $65,556 | |
| Nordicneurolab, Inc. | $6,209 | |
| Nordicneurolab, Inc. | $614,644 |
Quick answers
Who received award R01CA258788?
R01CA258788 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on March 21, 2022.
How much is award R01CA258788 worth?
$4,914,389 has been obligated on R01CA258788.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award